Aktuellt
SENASTE
We believe sales volumes for BD continued to normalise in Q2 and we expect a small contribution from Zimmer Biomet and growth in Wound Management. Overall, we see a return to y/y organic sales growth in Q2. The nature of the licence business model typically means high EBITDA margins (partners pay royalties on net sales). As Bactiguard is now fully focused on this area, sufficient scale in current and potential new license partnerships is crucial.
LÄS MER
